Follow-up study for children with primary hyperoxaluria type 1 treated with lumasiran
Part of Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study follows children who have primary hyperoxaluria type 1 (PH1) and are being treated with lumasiran. The goal is to monitor their health and treatment progress over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has a confirmed genetic diagnosis of primary hyperoxaluria type 1 (PH1).
- Your child has started treatment with lumasiran, either within the year before this study began or during the study period.
- If your child started lumasiran before the study, we need access to their treatment records and health history.
- Your child has not had a liver or kidney transplant.
- Your child is not currently on dialysis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients with primary hyperoxaluria type 1 who are being treated with Lumasiran. It aims to understand how well the treatment works over time.
This study tests a new treatment for primary hyperoxaluria type 1, a rare condition that causes too much oxalate in the body, which can lead to kidney stones and kidney damage. The treatment is given as an injection, and the study will see if it is safe and how the body responds.
This trial tests an experimental drug called YOLT-203 for people with type 1 primary hyperoxaluria (PH1), a rare condition that causes high oxalate levels and can damage the kidneys. It aims to see if YOLT-203 can safely help manage the disease.
This study tests a new drug called YOLT-203 for people with primary hyperoxaluria type 1 (PH1), a rare genetic condition where the body produces too much oxalate, which can damage the kidneys. The trial aims to see if this drug can help reduce oxalate levels and prevent kidney damage.
This Phase 2 study tests a medicine called DCR-PHXC to lower body oxalate levels in people with PH1 who have advanced kidney failure. By lowering oxalate, the treatment may reduce harm from oxalate buildup and help researchers understand safety and effectiveness.
This trial tests a new treatment called ABO-101 for people with primary hyperoxaluria type 1, a rare disease that causes high oxalate levels in urine. The study aims to see if ABO-101 can lower oxalate and protect kidney function.
Hear when a new Hyperoxaluria, Primary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.